1. Financial Services

  2. •

    Shell Companies
Frazier Lifesciences Acquisition Corp.

Frazier Lifesciences Acquisition Corp.

FLACW
Frazier Lifesciences Acquisition Corp.US flagNASDAQ Capital Market
0.80
USD
+0.03
- -
No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChatGPT
Sector
Financial Services
Industry
Shell Companies
Address
IPO Date
Feb 10, 2021
CIK
0001828326
Similar Companies
Deep Lake Capital Acquisition Corp. (DLCA)
Compute Health Acquisition Corp. (CPUH-UN)
Arogo Capital Acquisition Corp. (AOGOW)
TGE Value Creative Solutions Corp (BEBE)
InterPrivate III Financial Partners Inc. (IPVF-UN)
Viveon Health Acquisition Corp. (VHAQ-WT)
Business
Frazier Lifesciences Acquisition Corporation is a special purpose acquisition company (SPAC) primarily focused on identifying and merging with companies in the life sciences sector to facilitate their public listing. Incorporated in 2020 and headquartered in the Cayman Islands, the company is sponsored by an affiliate of Frazier Healthcare Partners. Its core business involves raising capital through its SPAC vehicle to target transformative healthcare and biopharmaceutical businesses. In a significant strategic development, Frazier Lifesciences Acquisition Corporation completed a reverse merger with NewAmsterdam Pharma Holding B.V., a late clinical-stage biopharmaceutical company specializing in the development of novel, oral therapies for major cardiometabolic diseases such as high-risk cardiovascular conditions. The combined entity, NewAmsterdam Pharma Company N.V., trades on Nasdaq under the ticker symbols "NAMS" and "NAMSW" since November 2022. The merger included a highly oversubscribed PIPE financing round of approximately $235 million, boosting the combined company’s pro forma cash position to support ongoing clinical development of obicetrapib, a next-generation cholesteryl ester transfer protein (CETP) inhibitor, planned through multiple clinical trials until 2026. This transaction marked a major strategic expansion and operational shift for the company, transitioning from a SPAC to a publicly traded biopharmaceutical company focused on innovative cardiovascular therapies. Additionally, the Frazier Life Sciences portfolio includes stakes in several biopharmaceutical and specialty pharmaceutical companies engaged in enzyme-based therapies, bispecific antibodies, topical medicines for skin diseases, and gastrointestinal treatments, reflecting its broad presence in life sciences innovation and commercialization. The company’s activities span the United States and Europe, supporting clinical development, commercialization, and strategic investments within the healthcare ecosystem. This description integrates Frazier Lifesciences Acquisition Corporation's transformation from an acquisition vehicle to a publicly listed biopharmaceutical company and highlights the latest major corporate change with the NewAmsterdam merger and capital raise, alongside its broader investment footprint in life sciences.